Arrowhead Pharmaceuticals, Inc. (ARWR) — Fair Value Analysis
Base-case fair value (P50): $39.10 · Current price: $81.82 · Verdict: Overvalued
Is ARWR overvalued based on Monte Carlo simulations?
The Verdict on ARWR
Our latest Monte Carlo simulations indicate that ARROWHEAD PHARMACEUTICALS INC (ARWR) is Deeply Overvalued. With ARWR currently trading at $81.82, our median fair value (P50) across thousands of forward-looking scenarios is significantly lower at $39.10. This considerable gap represents a potential -52.2% downside from the current price, underscoring the substantial premium the market is currently assigning to ARWR relative to its simulated intrinsic value. This divergence suggests a significant overestimation of future performance or a lack of attention to underlying operational realities compared to probabilistic outcomes.
How ARWR stacks up against peers
While ARROWHEAD PHARMACEUTICALS INC operates within a dynamic sector, its valuation, as determined by our Monte Carlo analysis, points to an elevated risk profile. The company's operational and financial health is currently assessed as "average" relative to its sector peers. This average quality tier suggests that while ARWR is not facing imminent distress, its fundamentals do not inherently justify the current market price of $81.82 when compared to the probabilistically derived median fair value of $39.10. Investors should consider that even with an average quality profile, the current valuation implies a bullish outlook not supported by a full spectrum of potential future outcomes.
What this means for investors
The pronounced -52.2% discrepancy between ARWR's current trading price of $81.82 and its Monte Carlo-derived median fair value of $39.10 signals caution for new and existing investors. The "Deeply Overvalued" verdict, coupled with an average quality tier, implies that the market may be pricing in optimal scenarios with insufficient discount for inherent risks or less favorable outcomes. For a comprehensive understanding of ARWR's potential price trajectories, including the bear (P10) and bull (P90) case scenarios, and to track its fair value as new fundamentals emerge, sign up for a free FairCurve account today.
Frequently Asked Questions
Is ARWR overvalued or undervalued right now?
Based on our Monte Carlo simulations, ARWR is currently deeply overvalued. Its current price of $81.82 significantly exceeds our median fair value estimate of $39.10.
What is the bear case and bull case for ARWR?
The full Monte Carlo distribution, including our bear (P10) and bull (P90) targets for ARWR, along with the probability of upside, is available exclusively to FairCurve account holders. We do not provide specific dollar values for these scenarios publicly.
How does FairCurve calculate ARWR's fair value?
FairCurve calculates ARWR's fair value by running Monte Carlo simulations across thousands of forward-looking financial scenarios. This probabilistic approach generates a robust range of potential outcomes, from which we derive a median fair value.
How can I track ARWR's fair value as it changes?
You can add ARWR to your free FairCurve watchlist to receive daily fair-value updates. Our system automatically re-evaluates the company's fair value instantly whenever new earnings or significant fundamental data are released.